URGN · Urogen Pharma Ltd. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $109.79M | $90.40M | $82.71M | $64.36M | $48.04M | $11.80M |
| Cost of Revenue | $12.45M | $8.88M | $9.36M | $7.65M | $5.16M | $1.01M |
| Gross Profit | $97.34M | $81.52M | $73.35M | $56.70M | $42.88M | $10.79M |
| R&D | $67.11M | $57.15M | $45.61M | $52.91M | $47.64M | $47.31M |
| SG&A | $155.10M | $121.15M | $93.27M | $82.84M | $87.53M | $90.22M |
| Total Operating Expenses | - | - | - | - | - | - |
| D&A | $307.0K | $329.0K | $802.0K | $924.0K | $831.0K | $400.0K |
| Operating Income | ($124.86M) | ($96.78M) | ($65.54M) | ($79.04M) | ($92.29M) | ($126.74M) |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | $78.0K | $2.83M | $3.92M | $1.75M | $1.45M | $3.37M |
| Net Income | ($153.49M) | ($126.87M) | ($102.24M) | ($109.78M) | ($110.82M) | ($128.48M) |
| EPS - Basic | ($3.19) | ($2.96) | ($3.55) | ($4.96) | - | - |
| EPS - Diluted | - | - | - | - | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $110.75M | $171.99M | $95.00M | $55.41M | $44.36M | $52.86M |
| Accounts Receivable | $33.08M | $20.30M | $15.44M | $12.70M | $11.72M | $7.05M |
| Inventory | $16.46M | $9.23M | $5.67M | $4.33M | $4.83M | $1.96M |
| Accounts Payable | $12.14M | $10.93M | $6.51M | $5.53M | $5.79M | $3.27M |
| Current Assets | $186.02M | $276.13M | $169.19M | $128.91M | $114.39M | $115.62M |
| Total Assets | $200.46M | $285.71M | $178.31M | $135.62M | $119.75M | $122.00M |
| Current Liabilities | $46.42M | $45.95M | $31.21M | $23.92M | $22.38M | $21.44M |
| Long-term Debt | $122.21M | $121.73M | $98.55M | $97.54M | - | - |
| Total Liabilities | $305.93M | $294.51M | $243.52M | $224.98M | $111.33M | $25.65M |
| Stockholders' Equity | ($105.47M) | ($8.80M) | ($65.21M) | ($89.36M) | $8.41M | $96.36M |
| Retained Earnings | ($959.72M) | ($806.22M) | ($679.35M) | ($577.10M) | ($467.32M) | ($356.50M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($162.44M) | ($96.77M) | ($76.38M) | ($87.56M) | ($84.89M) | ($105.89M) |
| Investing Cash Flow | $61.56M | ($20.61M) | ($953.0K) | $1.06M | $4.07M | $93.24M |
| Financing Cash Flow | $39.92M | $194.62M | $116.93M | $97.13M | $72.32M | $16.53M |
| CapEx | $289.0K | $295.0K | $194.0K | $254.0K | $752.0K | $1.22M |
| Free Cash Flow | ($162.73M) | ($97.06M) | ($76.57M) | ($87.81M) | ($85.64M) | ($107.10M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 88.7% | 90.2% | 88.7% | 88.1% | 89.3% | 91.4% |
| Operating margin | -113.7% | -107.1% | -79.2% | -122.8% | -192.1% | -1074.2% |
| EBITDA margin | -113.5% | -106.7% | -78.3% | -121.4% | -190.4% | -1070.8% |
| Net margin | -139.8% | -140.4% | -123.6% | -170.6% | -230.7% | -1088.9% |
| Free cash flow margin | -148.2% | -107.4% | -92.6% | -136.4% | -178.3% | -907.7% |
| FCF / Net income | 1.06 | 0.77 | 0.75 | 0.80 | 0.77 | 0.83 |
| R&D / Revenue | 61.1% | 63.2% | 55.1% | 82.2% | 99.2% | 401.0% |
| SG&A / Revenue | 141.3% | 134.0% | 112.8% | 128.7% | 182.2% | 764.6% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -76.6% | -44.4% | -57.3% | -80.9% | -92.5% | -105.3% |
| Return on equity | 145.5% | 1441.3% | 156.8% | 122.9% | -1317.2% | -133.3% |
| Return on invested capital | -589.4% | -67.7% | -155.3% | -763.7% | - | - |
| Liquidity | ||||||
| Current ratio | 4.01 | 6.01 | 5.42 | 5.39 | 5.11 | 5.39 |
| Quick ratio | 3.65 | 5.81 | 5.24 | 5.21 | 4.90 | 5.30 |
| Cash ratio | 2.39 | 3.74 | 3.04 | 2.32 | 1.98 | 2.47 |
| Leverage | ||||||
| Debt / Equity | -1.16 | -13.83 | -1.51 | -1.09 | - | - |
| Debt / Assets | 0.61 | 0.43 | 0.55 | 0.72 | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | -1.90 | -32.46 | -2.73 | -1.52 | 14.23 | 1.27 |
| Liabilities / Assets | 1.53 | 1.03 | 1.37 | 1.66 | 0.93 | 0.21 |
| Efficiency | ||||||
| Asset turnover | 0.55 | 0.32 | 0.46 | 0.47 | 0.40 | 0.10 |
| Inventory turnover | 0.76 | 0.96 | 1.65 | 1.77 | 1.07 | 0.51 |
| Days sales outstanding | 110d | 82d | 68d | 72d | 89d | 218d |
| Days inventory outstanding | 483d | 379d | 221d | 206d | 342d | 710d |
| Days payable outstanding | 356d | 449d | 254d | 264d | 410d | 1183d |
| Cash conversion cycle | 237d | 12d | 35d | 15d | 21d | -255d |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | 21.4% | 9.3% | 28.5% | 34.0% | 307.2% | 44.6% |
| Revenue CAGR (3y) | 19.5% | 23.5% | 91.4% | 99.1% | 249.2% | -12.4% |
| Revenue CAGR (5y) | 56.2% | 61.8% | 136.1% | 29.7% | - | - |
| Gross profit growth (YoY) | 19.4% | 11.1% | 29.4% | 32.2% | 297.5% | 59844.4% |
| Operating income growth (YoY) | -29.0% | -47.7% | 17.1% | 14.4% | 27.2% | -15.8% |
| Net income growth (YoY) | -21.0% | -24.1% | 6.9% | 0.9% | 13.7% | -22.2% |
| EPS growth (YoY) | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | -67.7% | -26.8% | 12.8% | -2.5% | 20.0% | -50.1% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -1098.2% | 86.5% | 27.0% | - | -91.3% | -46.6% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$109.79M totalJelmyto$93.99M · 85.6%
Zusduri$15.80M · 14.4%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-5.09
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✗Cash flow > net income
- ✗Long-term debt decreased
- ✗Current ratio improved
- -No share dilution
- ✗Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing UroGen Pharma Ltd. against the 5 most active filers in the same SIC group.